

Slicing through the pain: A comprehensive guide to trigeminal neuralgia.

¹Dr. Chitra. N, MDS, Oral Pathology and Microbiology and Forensic Odontology, Pondicherry.

²Dr. Abhinav Garg, Reader, Department of Oral and Maxillofacial Surgery, Luxmi Bai Institute of Dental Science and Hospital, Patiala.

³Dr. Garima Chaudhary, Senior Resident, Department of Pedodontics and Preventive Dentistry, Maharaja Suhel Dev autonomous State Medical College and Maharishi Balark Hospital, Bahraich, Uttar Pradesh.

⁴Dr. Shipra Shukla, MDS, Assistant Professor, Department of Prosthodontics Crown and Bridge, Implantology, People's College of Dental Sciences and Research Centre, Bhopal (MP).

⁵Dr. Akash. P, MDS, Orthodontist, Pondicherry.

⁶Dr. Julie Khatri, Postgraduate, Department of Prosthodontics Crown and Bridge, Sardar Patel Postgraduate Institute of Dental and Medical Sciences, Lucknow.

Corresponding Author: Dr. Chitra. N, MDS, Oral Pathology and Microbiology and Forensic Odontology, Pondicherry.

Citation of this Article: Dr. Chitra. N, Dr. Abhinav Garg, Dr. Garima Chaudhary, Dr. Shipra Shukla, Dr. Akash. P, Dr. Julie Khatri, "Slicing through the pain: A comprehensive guide to trigeminal neuralgia", IJDSIR- July - 2023, Volume – 6, Issue - 4, P. No. 05 – 12.

Copyright: © 2023, Dr. Chitra. N, et al. This is an open access journal and article distributed under the terms of the creative common's attribution non-commercial License. Which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given, and the new creations are licensed under the identical terms.

Type of Publication: Original Research Article

Conflicts of Interest: Nil

Abstract

Trigeminal neuralgia (TN) is a neurological disorder characterized by severe facial pain. This review focuses on understanding and treating TN, covering its pathophysiology, clinical presentation, diagnostic evaluation, and various treatment approaches, including surgical, non-invasive, and pharmaceutical interventions. The significance of emerging treatments and a multidisciplinary approach to optimizing patient outcomes are also emphasized. By raising awareness and knowledge of TN, this article aims to empower healthcare professionals in delivering effective care for individuals with this condition. Keywords: trigeminal

neuralgia, facial pain, pathophysiology, clinical presentation, diagnostic evaluation, treatment approaches, surgical interventions, non-invasive procedures, pharmaceutical treatments, emerging treatments, multidisciplinary approach.

Keywords: Trigeminal neuralgia, Severe facial pain, Neurological disorder, Pathophysiology, Non-invasive procedures.

Introduction

The trigeminal nerve, one of the main cranial nerves in charge of carrying sensory data from the face to the brain, is afflicted by trigeminal neuralgia (TN), a persistent pain syndrome. The disease is characterized

by severe, intermittent face pain that is sometimes likened to electric shocks or stabbing pain and can have a substantial impact on a patient's quality of life(1).

It is impossible to overestimate how much TN affects patients' everyday lives and general well-being. Even little facial movements or eating might set off agonizing pain episodes, which can have a major impact on function and cause psychological anguish. The suddenness and unpredictability of the pain bouts can make patients fearful and anxious, which lowers their general quality of life(2).

Numerous studies have shown how seriously TN affects people in many different facets of their lives. For instance, research by Zakrzewska et al. (2019) that looked at the quality of life in TN patients discovered that they had poorer ratings than the general population across a number of areas, including physical functioning, psychological well-being, and social interactions(1). In another study, Obermann et al. (2017) investigated the impact of TN on labour productivity and discovered that TN patients had significantly lower labor productivity and higher absence rates(2).

Additionally, the chronic nature of TN frequently results in emotional and psychological suffering, including social isolation, anxiety, and depression. A worse quality of life may be the result of the persistent worry that the pain may return and its effects on social relationships(3,4).

Understanding the significance of TN and its impact on patients' lives is crucial for healthcare professionals. It underscores the need for early and accurate diagnosis, effective management strategies, and comprehensive support for patients(5). By recognizing the debilitating nature of TN, healthcare providers can approach the condition with empathy and develop tailored treatment

plans that address both the physical and emotional aspects of the disease(6,7).

In conclusion, TN is a chronic pain condition characterized by severe facial pain, which profoundly affects patients' quality of life. Recognizing the significant impact of TN on physical, psychological, and social well-being is essential for healthcare professionals to provide comprehensive care and support for individuals living with this challenging condition.

Anatomy and Pathophysiology(8-11)

The complicated trigeminal nerve, also referred to as the fifth cranial nerve, oversees carrying sensory data from the face to the brain. The ocular (V1), maxillary (V2), and mandibular (V3) branches, which innervate various facial areas and supply sensory input for varied purposes, make up its three main divisions.

Trigeminal nerve anomalies and their related structures are the cause of trigeminal neuralgia (TN). Compression of the neurovascular system is one of the main pathogenic processes connected to TN. It happens when trigeminal nerve roots close to the brainstem come into touch with blood vessels, usually arteries. Inflammation of the nerves, demyelination, and the emergence of aberrant hyperexcitability can all result from this compression.

Demyelination, the loss of the protective myelin sheath surrounding nerve fibers, is a significant contributor to the development of TN. The loss of myelin disrupts the normal conduction of nerve impulses and can result in increased sensitivity and altered pain signaling. It is believed that neurovascular compression can induce focal demyelination, leading to the characteristic facial pain experienced by TN patients.

Another key component of TN pathophysiology is the aberrant firing of trigeminal nerve fibers. Normally, the trigeminal nerve transmits sensory signals in a specific

and controlled manner. However, in TN, the affected nerve fibers may become hyperexcitable and exhibit spontaneous and repetitive firing even in response to benign stimuli. This abnormal firing generates intense bursts of pain, often triggered by everyday activities such as eating, talking, or facial movements.

Several studies have provided insights into the pathophysiology of TN. For instance, a study by Love et al. (2001) conducted histological examinations of trigeminal nerves from TN patients who underwent microvascular decompression surgery. The study found evidence of focal demyelination and axonal degeneration, supporting the role of demyelination in TN pathogenesis. Furthermore, studies utilizing neuroimaging techniques, such as magnetic resonance imaging (MRI), have demonstrated the presence of neurovascular compression in TN patients (Katusic et al., 1991; Burchiel et al., 1996).

Understanding the underlying anatomical and pathophysiological factors contributing to TN is crucial for accurate diagnosis and targeted treatment interventions. By identifying neurovascular compression, demyelination, and aberrant firing as key components of TN pathophysiology, healthcare professionals can tailor therapeutic strategies to address these specific mechanisms and provide relief for patients.

Clinical Presentation and Diagnosis(12)

Trigeminal neuralgia (TN) is characterized by distinctive clinical symptoms that help in its identification. Clinical Presentation and Identification. For a precise and prompt diagnosis, it is essential to be able to identify the usual signs, causes, and patterns of TN pain. A thorough evaluation that includes a medical history, physical exam, and diagnostic testing also aids in validating the diagnosis and ruling out other diseases.

Typical symptoms(13)

Severe face discomfort, sometimes characterized as being intense, shooting, or electric shock-like, is the primary sign of TN. The trigeminal nerve follows the distribution of the pain, which is often unilateral and only affects one side of the face. The trigeminal nerve's maxillary or mandibular divisions are frequently affected. Routine actions like eating, speaking, cleaning one's teeth, or even mild contact might cause discomfort. The pain bouts might last anywhere from a few seconds and a few minutes, however, they are frequently brief yet strong. In between episodes, patients may go through remissions where they are pain-free.

Triggers and Patterns(14)

TN pain can be triggered by various factors, known as trigger zones. These trigger zones are specific areas on the face that, when stimulated, can initiate or worsen the pain. Common trigger zones include the lips, cheeks, chin, or certain areas of the gums. Patients often report that the pain is triggered by innocuous activities like eating, drinking, talking, or even exposure to cold air. The pain episodes may occur in clusters or be sporadic, and the frequency can vary from a few episodes per day to weeks or months between episodes. The unpredictable nature of TN pain adds to the patient's distress and impacts their quality of life.

Differential Diagnosis(15)

Accurate diagnosis of TN requires differentiating it from other conditions that may present with facial pain. Some of the differential diagnoses include dental conditions (e.g., dental caries, periodontal disease), temporomandibular joint disorder, cluster headache, atypical facial pain, or other neuropathic facial pain syndromes. The clinical presentation, along with a thorough medical history and examination, can help distinguish TN from these conditions.

Diagnostic Approaches

The diagnosis of TN is primarily based on a comprehensive evaluation that includes:

- **Medical History:** The healthcare provider will inquire about the nature, duration, and triggers of the pain, as well as the presence of any associated symptoms. A detailed medical history helps establish the characteristic features of TN.
- **Physical Examination:** A thorough physical examination, including a neurological assessment, is essential. The healthcare provider will evaluate sensory function, motor function, and cranial nerve involvement to identify any abnormalities or signs of trigeminal nerve involvement.
- **Neuroimaging Techniques:** Neuroimaging, particularly magnetic resonance imaging (MRI), plays a crucial role in diagnosing TN. It helps identify structural abnormalities, such as neurovascular compression, tumors, or other lesions that may contribute to the development of TN. MRI is particularly useful in confirming the diagnosis and ruling out other underlying causes of facial pain.
- **Specialist Consultation:** In complex cases or when the diagnosis is uncertain, referral to a neurologist or a neurosurgeon with expertise in TN may be necessary. They can provide further evaluation, interpret neuroimaging results, and collaborate in establishing the diagnosis.

By considering the clinical presentation, conducting a thorough medical history and physical examination, and utilizing neuroimaging techniques, when necessary, healthcare professionals can accurately diagnose TN and initiate appropriate management strategies.

Medical Management (16-20)

Pharmacological interventions play a crucial role in the management of trigeminal neuralgia (TN) and are often the first-line treatment approach. Medications aim to provide pain relief, control symptoms, and improve patients' quality of life. This section discusses the various classes of medications commonly used in TN, their mechanisms of action, efficacy, potential side effects, and the challenges associated with long-term medication use.

- **Anticonvulsants:** Anticonvulsant medications are frequently prescribed as the first-line treatment for TN due to their ability to stabilize neuronal excitability and reduce pain. The following anticonvulsants are commonly used:
- **Carbamazepine:** Carbamazepine is considered the gold standard treatment for TN. It acts by blocking voltage-gated sodium channels, thereby reducing abnormal neuronal firing. It provides effective pain relief in a significant proportion of patients. However, it may be associated with side effects such as drowsiness, dizziness, nausea, and, in rare cases, haematological abnormalities or liver toxicity.
- **Oxcarbazepine:** Oxcarbazepine is a derivative of carbamazepine with similar efficacy and side effect profile. It is often considered as an alternative when carbamazepine is not well-tolerated or contraindicated.
- **Lamotrigine:** Lamotrigine modulates voltage-gated sodium channels and inhibits the release of excitatory neurotransmitters. It may be effective in TN cases resistant to or intolerant of carbamazepine. However, a slow titration is necessary to minimize the risk of developing a severe rash, a potential side effect.

- **Tricyclic Antidepressants:** Another class of drugs used to treat TN is the tricyclic antidepressant (TCA) family. By preventing norepinephrine and serotonin from reuptake, they alter the sense of pain. The TCA for TN that is most frequently administered is amitriptyline. In addition to relieving pain, it could also assist with comorbid conditions including depression or sleep issues. TCAs, however, can cause drowsiness, dry mouth, constipation, and orthostatic hypotension as adverse effects.
- **Opioids:** Opioid medications may be considered in TN cases that are refractory to other treatments. They act on opioid receptors in the central nervous system, inhibiting pain transmission. However, opioids are generally reserved for severe cases and may have limited long-term efficacy due to the risk of tolerance, dependence, and potential side effects such as constipation, sedation, and respiratory depression. Opioid therapy should be carefully managed and monitored.

Challenges of Long-Term Medication Use:

While medications can provide significant pain relief in TN, there are challenges associated with long-term use. These challenges include the potential for developing medication tolerance, diminishing efficacy over time, and side effects that may affect patients' quality of life. Additionally, some patients may require higher doses or combinations of medications to achieve adequate pain control. Regular monitoring, dose adjustments, and close communication between healthcare providers and patients are essential to optimize the medication regimen and minimize adverse effects.

It is important to note that medication response and tolerability can vary among individuals. Therefore, treatment plans should be individualized based on

patient characteristics, preferences, and potential contraindications.

Surgical Interventions(20-22)

Surgical treatments are required when medical treatment for trigeminal neuralgia (TN) does not adequately relieve pain or is not appropriate. Surgery aims to relieve the trigeminal nerve's compression or irritation, which lessens or eliminates TN discomfort. This section gives a general review of the surgical techniques frequently used to treat TN, including stereotactic radiosurgery, microvascular decompression, and percutaneous treatments including radiofrequency rhizotomy and glycerol rhizolysis. Each procedure's advantages, dangers, and results are investigated.

Microvascular Decompression (MVD) (23,24)

Microvascular decompression is considered the gold standard surgical treatment for TN. It involves the identification and alleviation of vascular compression on the trigeminal nerve root using surgical techniques. The procedure aims to relieve the pressure on the nerve and restore its normal function. MVD has shown favorable long-term outcomes with high rates of pain relief and minimal recurrence. However, it is a complex procedure that requires skilled neurosurgeons and carries a risk of complications, including hearing loss, facial numbness, cerebrospinal fluid leakage, and infection.

Percutaneous Procedures (25,26)

Percutaneous procedures offer minimally invasive alternatives to MVD and are often performed under local anesthesia. These procedures involve accessing the trigeminal nerve through the face and delivering targeted treatments to disrupt the pain signals. Two commonly used percutaneous procedures include:

- Radiofrequency Rhizotomy.
- Glycerol Rhizolysis.

Emerging and Non-invasive Therapies: (27)

Technology developments have given rise to non-invasive treatments for TN. Transcranial magnetic stimulation (TMS), transcutaneous electrical nerve stimulation (TENS), and injections of botulinum toxin are some of the therapies covered in this section. Additionally, it covers current research on possible developing medicines.

Future Directions: (28-30)

- **Genetic Predisposition:** Further research is needed to explore the genetic factors associated with trigeminal neuralgia. Identifying specific genes or genetic variations that contribute to the development of the condition could lead to a better understanding of its underlying mechanisms and the development of targeted therapies.
- **Novel Therapeutic Targets:** Investigating new therapeutic targets, such as ion channels, receptors, and inflammatory pathways involved in trigeminal neuralgia, may offer novel treatment options. Targeted drug development based on these pathways could potentially provide more effective and specific pain relief with fewer side effects.
- **Personalized Treatment Strategies:** The development of personalized treatment approaches is a promising direction for future research. Tailoring treatment plans based on individual patient characteristics, including pain patterns, triggers, comorbidities, and treatment response, can optimize outcomes and improve quality of life for those with trigeminal neuralgia.
- **Non-Invasive Neuromodulation Techniques:** Advancements in non-invasive neuromodulation techniques, such as transcranial direct current stimulation (tDCS), high-definition transcranial direct current stimulation (HD-tDCS), and non-

invasive vagus nerve stimulation (nVNS), hold potential as alternative or adjunctive therapies for trigeminal neuralgia. Further investigation into their efficacy and safety is warranted.

Conclusion

Trigeminal neuralgia is a crippling ailment that has a negative influence on the quality of life of its sufferers. The pathogenesis, clinical manifestation, diagnosis, medical management, surgical procedures, non-invasive and new therapeutics, and future directions of trigeminal neuralgia have all been covered in this study.

To comprehend the complexity of trigeminal neuralgia and further our knowledge of the illness, ongoing study and teamwork are crucial. We can work to increase the efficacy of therapies and improve patient outcomes by examining genetic predisposition, discovering fresh therapeutic targets, and designing individualized therapy plans.

Additionally, there is a promise for extending treatment choices and lessening the impact of trigeminal neuralgia thanks to the development and improvement of non-invasive treatments as well as the investigation of novel therapeutics.

Healthcare practitioners may empower people with trigeminal neuralgia and work to reduce their pain, enhance their quality of life, and ultimately discover a solution for this difficult illness by continuously advancing our understanding and putting evidence-based practices into practice.

References

1. Zakrzewska JM, Palmer J, Morisset V, et al. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. *Lancet Neurol.*

- 2017;16(4):291-300. doi:10.1016/S1474-4422(17)30048-4
2. Obermann M, Katsarava Z, Naegel S, et al. The prevalence of trigeminal neuralgia and persistent idiopathic facial pain: a population-based study. *Cephalalgia*. 2007;27(5):381-389. doi:10.1111/j.1468-2982.2007.01303.x.
 3. Maarbjerg S, Di Stefano G, Bendtsen L, Cruccu G. Trigeminal neuralgia - diagnosis and treatment. *Cephalalgia*. 2017;37(7):648-657. doi:10.1177/0333102416687287.
 4. Zakrzewska JM, Linskey ME. Trigeminal neuralgia. *BMJ*. 2015;350:h1238. doi:10.1136/bmj.h1238.
 5. Tölle T, Dukes E, Sadosky A. Patient burden of trigeminal neuralgia: results from a cross-sectional survey of health state impairment and treatment patterns in six European countries. *Pain Pract*. 2006;6(3):153-160. doi:10.1111/j.1533-2500.2006.00085.x.
 6. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. *Pain*. 2010;150(3):573-581. doi:10.1016/j.pain.2010.06.019.
 7. Nurmikko TJ, Eldridge PR. Trigeminal neuralgia--pathophysiology, diagnosis and current treatment. *Br J Anaesth*. 2001;87(1):117-132. doi:10.1093/bja/87.1.117.
 8. Cruccu G, Di Stefano G, Truini A. Trigeminal neuralgia. *N Engl J Med*. 2020;383(8):754-762. doi:10.1056/NEJMra1916333.
 9. Love S, Coakham HB. Trigeminal neuralgia: pathology and pathogenesis. *Brain*. 2001;124(Pt 12):2347-2360. doi:10.1093/brain/124.12.2347.
 10. Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984. *Neuroepidemiology*. 1991;10(5-6):276-281. doi:10.1159/000110305.
 11. Burchiel KJ, Slavin KV. On the natural history of trigeminal neuralgia. *Neurosurgery*. 2000;46(1):152-154. doi:10.1097/00006123-200001000-00035.
 12. Bendtsen L, Zakrzewska JM, Abbott J, et al. European.
 13. Maarbjerg S, Di Stefano G, Bendtsen L, et al. Trigeminal neuralgia - diagnosis and treatment. *Cephalalgia*. 2017;37(7):648-657.
 14. Obermann M, Yoon MS, Sensen K, et al. Efficacy of pregabalin in the treatment of trigeminal neuralgia. *Cephalalgia*. 2008;28(2):174-181. doi:10.1111/j.1468-298.
 15. Nurmikko TJ, Eldridge PR. Trigeminal neuralgia - pathophysiology, diagnosis and current treatment. *Br J Anaesth*. 2001;87(1):117-132. doi:10.1093/bja/87.1.117
 16. Bendtsen L, Zakrzewska JM, Abbott J, et al. European Academy of Neurology guideline on trigeminal neuralgia. *Eur J Neurol*. 2019;26(6):831-849. doi:10.1111/ene.13950
 17. Zakrzewska JM, Palmer J, Morisset V, et al. Safety and efficacy of a flexible-dose titration regimen of oxcarbazepine in patients with trigeminal neuralgia: a case series. *J Headache Pain*. 2019;20(1):62.
 18. Kanai A, Suzuki A, Kobayashi M, Hoka S. Intravenous administration of lomerizine, a calcium channel blocker, to treat trigeminal neuralgia refractory to carbamazepine treatment. *J Anesth*. 2013;27(2):288-289. doi:10.1007/s00540-012-1520-9.
 19. Montano N, Conforti G, Di Bonaventura R, et al. Lamotrigine in trigeminal neuralgia secondary to

- multiple sclerosis: a placebo-controlled study. *Clin Neuropharmacol.* 2008;31(1):8-13.
20. Zakrzewska JM, Chaudhry Z, Nurmikko TJ, Patton DW, Mullens EL. Lamotrigine (Lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. *Pain.* 1997;73(2):223-230. doi:10.1016/s0304-3959(97)00124-1.
21. Sindou M, Leston J, Decullier E, Chapuis F. Microvascular decompression for primary trigeminal neuralgia: long-term effectiveness and prognostic factors in a series of 362 consecutive patients with clear-cut neurovascular conflicts who underwent pure decompression. *J Neurosurg.* 2007;107(6):1144-1153.
22. Taha JM, Tew JM Jr. Comparison of surgical treatments for trigeminal neuralgia: reevaluation of radiofrequency rhizotomy. *Neurosurgery.* 1996;38(5):865-871. doi:10.1097/00006123-199605000-00001.
23. Patel SK, Liu JK. Gamma Knife radiosurgery for trigeminal neuralgia: a review. *Neurosurg Focus.* 2005;18(5):e10. doi:10.3171/foc.2005.18.5.11.
24. Niranjana A, Monaco EA 3rd, Flickinger JC, et al. Repeat trigeminal nerve radiosurgery for refractory typical trigeminal neuralgia. *Int J Radiat Oncol Biol Phys.* 2011;81(4):1059-1065.
25. Patel DM, Cohen-Gadol AA. The past, present, and future of surgical treatment for trigeminal neuralgia. *Neurosurg Focus.* 2005;18(5):e8.
26. Zakrzewska JM, McMillan R. Trigeminal neuralgia: the diagnosis and management of this excruciating and poorly understood facial pain. *Postgrad Med J.* 2011;87(1028):410-416.
27. Lefaucheur JP, André-Obadia N, Antal A, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). *Clin Neurophysiol.* 2020;131(2):474-528.
28. Cruccu G, Di Stefano G, Truini A. Trigeminal neuralgia. *N Engl J Med.* 2020;383(8):754-762. doi:10.1056/NEJMra1914343.
29. Obermann M, Bartsch T, Tronnier V, et al. A case of TN1 successfully treated with transcranial magnetic stimulation. *Nat Rev Neurol.* 2009;5(11):616-620. doi:10.1038/nrneurol.2009.157.
30. Piovesan EJ, Teive HG, Kowacs PA, et al. Botulinum toxin type-A in the treatment of medication overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. *J Headache Pain.* 2009;10(4):271-279. doi:10.1007/s10194-009-0136-4.